Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
CAMBRIDGE, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler , President and CEO, will present at
View HTML
Toggle Summary Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results
— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG transfer in perfusion model of the human term placenta, published in American Journal of Obstetrics & Gynecology — — First
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
- Data highlight potential of Fc multimerization technology platform to significantly enhance the potency and efficacy of therapeutic antibodies - CAMBRIDGE, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn    Global multi-center Phase 2 study of M281 in hemolytic disease of the fetus and newborn (HDFN) now active following
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 trial of M254 in immune thrombocytopenia (ITP) -- CAMBRIDGE, Mass. , Feb.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion model M281 currently being evaluated in an international Phase 2 study in Hemolytic Disease of the Fetus and Newborn (HDFN) CAMBRIDGE, Mass. , Feb.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the dosing of the first subject in the Phase 1/2
View HTML